Argenica Therapeutics (ASX:AGN) functional gains strengthen case for next phase of stroke drug
Argenica Therapeutics (ASX:AGN) has released promising data from its Phase 2 clinical trial of ARG-007, a neuroprotective peptide designed to…
Argenica Therapeutics (ASX:AGN) has released promising data from its Phase 2 clinical trial of ARG-007, a neuroprotective peptide designed to…
Argenica Therapeutics may have cracked the code on treating brain injury, with a ferret study showing its lead drug ARG-007 delivers lasting protection where no approved therapy exists.
Argenica Therapeutics has secured a new US patent that positions its lead drug, ARG-007, at the forefront of preventing stroke not just in emergency rooms, but in operating theatres
Argenica Therapeutics’ ARG-007 has demonstrated compelling neuroprotective effects in preclinical models of traumatic brain injury, reducing brain cell damage and neuroinflammation to levels comparable with non-injured subjects.
Argenica Therapeutics (ASX:AGN) moves closer to a potential breakthrough in stroke treatment as its Phase 2 trial of ARG-007 nears completion with a final safety endorsement from the DSMB.
Argenica Therapeutics (ASX:AGN) has dosed 80% of patients in its Phase 2 trial for ARG-007, a promising stroke therapy, with no adverse safety concerns reported.
Argenica Therapeutics advances its stroke treatment with ARG-007, achieving a key safety milestone in its Phase 2 trial, signalling promising potential for brain injury recovery.